natgillin/translations-raw huggingface dataset:
In the second study, treatment failed in 30% (68 out of 277) of the patients adding Rapamune, compared with 48% (62 out of 130) of those adding placebo. 
V drugi študiji je bilo zdravljenje neuspešno pri 30 % (68 od 277) bolnikov, ki so jim dodajali zdravilo Rapamune, in pri 48 % (62 od 130) bolnikov, ki so jim dodajali placebo.
The European Medicines Agency considered that Rapamune is effective for the prevention of rejection of a transplanted kidney in patients at low to moderate risk of rejection. 
Evropska agencija za zdravila je presodila, da je zdravilo Rapamune učinkovito pri preprečevanju zavrnitve presajene ledvice pri bolnikih z majhnim do zmernim tveganjem za zavrnitev organa.
Rapamune contains the active substance sirolimus. 
Zdravilo Rapamune vsebuje učinkovino sirolimus.
In the first study, treatment failed in 19% (53 out of 284) of the patients adding Rapamune after 6 months, compared with 32% (52 out of 161) of those adding azathioprine. 
V prvi študiji je bilo zdravljenje po šestih mesecih neuspešno pri 19 % (53 od 284) bolnikov, ki so jim dodajali zdravilo Rapamune, in pri 32 % (52 od 161) bolnikov, ki so jim dodajali azatioprin.
The Agency noted that no medicinal product has been approved for the treatment of S-LAM and Rapamune's effect on lung function is considered important. 
Ugotovila je, da za zdravljenje S-LAM še ni odobreno nobeno zdravilo in da je učinek zdravila Rapamune na delovanje pljuč pomemben.
Rapamune was effective in helping the new kidney to survive, with an improvement in how well it worked and an improvement in blood pressure when ciclosporin treatment was stopped. 
Zdravilo Rapamune je bilo učinkovito in je prispevalo k preživetju in boljšemu delovanju nove ledvice ter izboljšanju krvnega tlaka po prenehanju jemanja ciklosporina.
By blocking mTOR, Rapamune reduces the multiplication of these cells. 
Zdravilo Rapamune z zaviranjem mTOR zmanjša razmnoževanje teh celic.
For the full list of side effects and restrictions of Rapamune, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Rapamune glejte navodilo za uporabo.
Rapamune is a medicine used to prevent the body from rejecting a newly transplanted kidney. 
Rapamune je zdravilo, ki se uporablja za preprečevanje zavrnitve ledvice po presaditvi.
How is Rapamune used? 
Kako se zdravilo Rapamune uporablja?
Rapamune was more effective than placebo in improving lung function in a study involving 81 patients with S-LAM. 
Zdravilo Rapamune je bilo v študiji, v katero je bilo vključenih 81 bolnikov s S-LAM, pri izboljšanju delovanja pljuč učinkovitejše od placeba.
How does Rapamune work? 
Kako zdravilo Rapamune deluje?
Rapamune treatment should be started by and remain under the guidance of a doctor who is a qualified specialist in transplantation. 
Zdravljenje z zdravilom Rapamune sme uvesti in pozneje nadzorovati le usposobljen zdravnik specialist za presaditve.
(Invented) Name Strength 
(Izmišljeno) ime
Tesavel is taken at a dose of 100 mg once a day. 
Zdravilo Tesavel se jemlje v odmerku 100 mg enkrat na dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Tesavel on 10 January 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Tesavel, veljavno po vsej Evropski uniji, odobrila dne 10. januarja 2008.
The full EPAR for Tesavel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tesavel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This authorisation was based on the authorisation granted to Januvia in 2007 (‘informed consent'). 
Ta odobritev je temeljila na dovoljenju za promet, odobrenemu zdravilu Januvia leta 2007 (uporaba dokumentacije s soglasjem).
Other information about Tesavel 
Druge informacije o zdravilu Tesavel
This is a summary of the European public assessment report (EPAR) for Tesavel. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tesavel.
For more information about treatment with Tesavel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tesavel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefit has Tesavel shown during the studies? 
Kakšne koristi je zdravilo Tesavel izkazalo med študijami?
In patients with moderately or severely reduced kidney function the dose of Tesavel should be reduced. 
Pri bolnikih z delno ali močno okrnjenim delovanjem ledvic je treba odmerek zdravila Tesavel zmanjšati.
Tesavel must not be used in people who are hypersensitive (allergic) to sitagliptin or any of the other ingredients. 
Zdravila Tesavel ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) sitagliptin ali katero koli drugo sestavino zdravila.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tesavel. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Tesavel, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
If Tesavel is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood sugar levels). 
Če se zdravilo Tesavel jemlje s sulfonilsečnino ali insulinom, bo morda treba odmerek sulfonilsečnine ali insulina znižati, da se zmanjša tveganje za hipoglikemijo (nizko koncentracijo sladkorja v krvi).
In the studies comparing Tesavel with other medicines, the effectiveness of adding Tesavel to metformin was similar to that of adding glipizide. 
V študijah, v katerih so zdravilo Tesavel primerjali z drugimi zdravili, je bila učinkovitost dodajanja zdravila Tesavel metforminu podobna kot pri dodajanju glipizida.
What is the risk associated with Tesavel? 
Kakšna tveganja so povezana z zdravilom Tesavel?
The active substance in Tesavel, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. 
Zdravilna učinkovina zdravila Tesavel je sitagliptin, ki je zaviralec dipeptidil peptidaze-4 (DPP-4).
Tesavel is a medicine that contains the active substance sitagliptin. 
Tesavel je zdravilo, ki vsebuje zdravilno učinkovino sitagliptin.
Tesavel was studied in nine studies involving almost 6,000 patients with type 2 diabetes whose blood glucose levels were not adequately controlled: 
Zdravilo Tesavel je bilo raziskano v devetih glavnih študijah, ki so vključevale skoraj 6 000 bolnikov s sladkorno boleznijo tipa 2, pri katerih ravni glukoze v krvi niso bile zadostno nadzorovane:
• two studies compared Tesavel with other antidiabetes medicines. 
• v dveh študijah so zdravilo Tesavel primerjali z drugimi zdravili proti sladkorni bolezni.
Tesavel was more effective than placebo when it was taken alone or in combination with other antidiabetes medicines. 
Zdravilo Tesavel je bilo učinkovitejše od placeba, ko so ga bolniki jemali kot samostojno zdravilo ali v kombinaciji z drugimi zdravili proti sladkorni bolezni.
The CHMP decided that Tesavel's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tesavel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Serious side effects reported with Tesavel include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions). 
Med resnimi neželenimi učinki, o katerih so poročali pri uporabi zdravila Tesavel so pankreatitis (vnetje trebušne slinavke) in preobčutljivostne (alergijske) reakcije.
Tesavel is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels. 
Zdravilo Tesavel se uporablja za zdravljenje bolnikov s sladkorno boleznijo tipa 2 za izboljšanje nadzora nad ravnjo glukoze (sladkorja) v krvi.
In patients taking Tesavel on its own, HbA1c levels fell from around 8.0% at the start of the studies by 0.48% after 18 weeks and 0.61% after 24 weeks. 
Pri bolnikih, ki so jemali samo zdravilo Tesavel so se ravni HbA1c zmanjšale za približno 8 % na začetku študij, za 0,48 % po 18 tednih in za 0,61 % po
For the full list of all side effects reported with Tesavel, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tesavel, glejte navodilo za uporabo.
Why has Tesavel been approved? 
Zakaj je bilo zdravilo Tesavel odobreno?
• three additional studies compared Tesavel with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients. 
• v treh dodatnih študijah so zdravilo Tesavel primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR-gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
When taken on their own, Tesavel and metformin produced similar reductions in HbA1c levels, but the effectiveness of Tesavel seemed to be slightly lower than that of metformin. 
Ob samostojnem jemanju zdravila Tesavel ali metformina so bila znižanja ravni HbA1c podobna, vendar je bilo zdravilo Tesavel malenkost slabše učinkovito kot metformin.
The other study compared Tesavel with metformin, used on their own, in 1,058 patients; 
V drugi študiji so zdravilo Tesavel primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno;
• in combination with both metformin and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines; 
• v kombinaciji z metforminom in sulfonilsečnino ali agonistom PPAR-gama pri bolnikih, pri katerih z obema zdraviloma ni vzpostavljen zadosten nadzor;
• on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (an antidiabetes medicine) is not suitable; 
• kot samostojno zdravilo pri bolnikih, katerih bolezen samo z dieto in telesno vadbo ni zadovoljivo nadzorovana in pri katerih metformin (zdravilo za zdravljenje sladkorne bolezni) ni primeren;
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Tesavel to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo. 
Ravni HbA1c so bile po 18 tednih znižane za 1,03 % pri bolnikih, ki so zdravilo Tesavel dodajali metforminu in rosiglitazonu, v primerjavi z znižanjem za 0,31 % pri tistih, ki so kot dodatek prejemali placebo.
Finally, they were reduced by 0.59% in patients adding Tesavel to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo. 
Ravni so se znižale za 0,59 % pri bolnikih, ki so zdravilo Tesavel dodajali insulinu (z metforminom ali brez njega) v primerjavi z zmanjšanjem za 0,03 % pri tistih, ki so kot dodatek jemali placebo.
Tesavel or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients; 
• v štirih študijah so zdravilo Tesavel primerjali s placebom (zdravilom brez zdravilne učinkovine): zdravilo Tesavel ali placebo so bolniki jemali samostojno v dveh študijah, ki sta vključevali 1 262 bolnikov, kot dodatek metforminu v eni študiji s 701 bolnikom in kot dodatek pioglitazonu (agonistu PPAR-gama) v eni študiji s 353 bolniki;
How does Tesavel work? 
Kako zdravilo Tesavel deluje?
In the additional studies, adding Tesavel to glimepiride (with and without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in the patients adding placebo. 
V dodatnih študijah je dodajanje zdravila Tesavel glimepiridu (z metforminom ali brez njega) po 24 tednih znižalo ravni HbA1c za 0,45 % v primerjavi s povečanjem za 0,28 % pri bolnikih, pri katerih so dodajali placebo.
What is Tesavel used for? 
Za kaj se zdravilo Tesavel uporablja?
How has Tesavel been studied? 
Kako je bilo zdravilo Tesavel raziskano?
What is Tesavel? 
Kaj je zdravilo Tesavel?
One study compared Tesavel with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients. 
V eni študiji so pri 1 172 bolnikih primerjali zdravilo Tesavel z glipizidom (sulfonilsečnino), obe zdravili pa so dodajali metforminu.
When added to pioglitazone, Tesavel reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo. 
Če je bilo zdravilo Tesavel dodano pioglitazonu, je po 24 tednih znižalo ravni HbA1c za 0,85 % v primerjavi z znižanjem za 0,15 % pri bolnikih, ki so kot dodatek jemali placebo.
Adding Tesavel to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo. 
Če je bilo zdravilo Tesavel dodano metforminu, je po 24 tednih znižalo ravni HbA1c za 0,67 % v primerjavi z znižanjem za 0,02 % pri bolnikih, ki so kot dodatek jemali placebo.
How is Tesavel used? 
Kako se zdravilo Tesavel uporablja?
This may limit the damage to nearby healthy tissues. 
To lahko omeji poškodbo na bližnja zdrava tkiva.
1 See outcome of safety review carried out in 2018 here. 
1 Izid varnostnega pregleda, opravljenega v letu 2018, si lahko ogledate tukaj.
Further information on Xofigo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu Xofigo so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It should be used only for patients who have had at least two previous treatments for prostate cancer or who cannot receive other treatments. 
Uporabljati se sme samo pri bolnikih, pri katerih sta bili neuspešni vsaj dve predhodni zdravljenji raka prostate ali ki ne morejo prejeti drugih zdravil.
The bones in the body take up radium in the same way as calcium. 
Kosti v telesu radij privzemajo enako kot kalcij.
What measures are being taken to ensure the safe and effective use of Xofigo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xofigo?
The European Medicines Agency decided that Xofigo's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Xofigo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Xofigo received a marketing authorisation valid throughout the EU on 13 November 2013. 
Za zdravilo Xofigo je bilo 13. novembra 2013 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Xofigo 
Druge informacije o zdravilu Xofigo
Patients given Xofigo lived on average for 14.9 months, compared with 11.3 months for those given placebo. 
Bolniki, ki so prejemali Xofigo, so preživeli 14,9 meseca, tisti, ki so prejemali placebo, pa 11,3 meseca.
Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection. 
Bolniki so v enomesečnih razmikih prejeli do šest injekcij, spremljali pa so jih do tri leta od prvega injiciranja.
Injections are repeated every 4 weeks for a total of 6 injections. 
Injiciranje je treba ponavljati vsake štiri tedne, bolnik pa skupno prejme šest injekcij.
As for all medicines, data on the use of Xofigo are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xofigo stalno spremljajo.
The medicine is slowly injected into a vein usually for up to one minute. 
Zdravilo se počasi, običajno do največ eno minuto, injicira v veno.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xofigo have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xofigo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Xofigo must not be used with the medicine abiraterone acetate and the corticosteroids prednisone or prednisolone. 
Zdravilo Xofigo se ne sme uporabljati z abirateron acetatom ali kortikosteroidom prednizonom ali prednizolonom.
The radioactive radium builds up in bone tissues where the cancer has spread, and the alpha particles destroy surrounding cancer cells and help to control the associated symptoms. 
Radioaktivni radij se kopiči v kostnih tkivih, v katere se je razširil rak, delci alfa pa uničujejo okoliške rakave celice in pomagajo nadzorovati simptome bolezni.
The most serious side effects were thrombocytopenia and neutropenia (low levels of neutrophils, a type of white blood cell that fights infection). 
Najresnejša neželena učinka sta bila trombocitopenija in nevtropenija (nizko število nevtrofilcev, vrste belih krvnih celic, ki se borijo proti okužbam).
Side effects reported with Xofigo are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Xofigo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What benefits of Xofigo have been shown in studies? 
Kakšne koristi zdravila Xofigo so se pokazale v študijah?
Why is Xofigo authorised in the EU? 
Zakaj je bilo zdravilo Xofigo odobreno v EU?
An overview of Xofigo and why it is authorised in the EU 
Pregled zdravila Xofigo in zakaj je odobreno v EU
The dose of Xofigo is calculated to provide a specific dose of radioactivity based on the patient's body weight. 
Odmerek zdravila Xofigo se izračuna za zagotovitev točnega odmerka radioaktivnosti na podlagi bolnikove telesne mase.
Xofigo is used on its own or in combination with a medicine known as an ‘LHRH analogue'. 
Zdravilo Xofigo se uporablja samostojno ali v kombinaciji z zdravilom, imenovanim analog LHRH.
Xofigo has been shown to prolong life and delaying signs and symptoms of progressive disease. 
Dokazano je, da zdravilo Xofigo podaljša življenje in odloži pojav znakov in simptomov napredujoče bolezni.
The company that markets Xofigo will have to conduct studies to further characterise the safety profile of the medicine, in particular with regard to the risk of fractures and the risk of new metastases that do not affect the bone in patients treated with Xofigo. 
Podjetje, ki trži zdravilo Xofigo, bo moralo izvesti študije za nadaljnjo opredelitev varnostnega profila tega zdravila, zlasti kar zadeva tveganje za zlome in tveganje za nove zasevke, ki ne prizadenejo kosti, pri bolnikih, zdravljenih s tem zdravilom.
For more information about using Xofigo, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Xofigo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Xofigo is a radiopharmaceutical (a medicine containing a radioactive substance) that is used to treat adults with cancer of the prostate (a gland of the male reproductive system). 
Zdravilo Xofigo je radiofarmak (zdravilo, ki vsebuje radioaktivno snov), ki se uporablja za zdravljenje odraslih z rakom prostate (žleze moškega reproduktivnega sistema).
What are the risks associated with Xofigo? 
Kakšna tveganja so povezana z zdravilom Xofigo?
Xofigo is used when castration (to stop the production of male hormones) by surgery or with medicines does not work, and when the cancer has spread to the bones (bone metastases) and is causing symptoms such as pain, but has not spread to other internal organs. 
Zdravilo Xofigo se uporablja, kadar je kastracija (za prenehanje tvorbe moških hormonov) s kirurškim posegom ali zdravili neučinkovita ali kadar se je rak razširil na kosti (kostne metastaze) in povzroča simptome, kot je bolečina, ni pa se razširil na druge notranje organe.
Xofigo can only be obtained with a prescription and should only be handled and given by someone who is authorised to use radioactive medicines and after evaluation of the patient by a qualified doctor. 
Predpisovanje in izdaja zdravila Xofigo je le na recept, z njim pa sme ravnati in ga dajati samo oseba, ki je pooblaščena za uporabo radioaktivnih zdravil, in sicer po tem, ko je bolnika pregledal usposobljeni zdravnik.
What is Xofigo and what is it used for? 
Kaj je zdravilo Xofigo in za kaj se uporablja?
Xofigo can increase the risk of having fractures. 
Zdravilo Xofigo lahko poveča tveganje za pojav zlomov.
Xofigo (radium-223 dichloride) 
Xofigo ([223Ra]radijev klorid)
Xofigo was compared with placebo (a dummy treatment) as an addition to standard care in a main study involving 921 men with cancer of the prostate that had spread to the bones and for which suppression of male hormones using medicines or surgery did not work. 
Zdravilo Xofigo so s placebom (zdravilom brez učinkovine) poleg standardne nege primerjali v glavni študiji, v katero je bilo vključenih 921 moških z rakom prostate, ki se je razširil na kosti, pri katerih supresija moških hormonov z zdravili ali kirurškim posegom ni bila učinkovita.
The most common side effects with Xofigo (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting, thrombocytopenia (low blood-platelet counts) and bone fractures. 
Najpogostejši neželeni učinki zdravila Xofigo (ki se lahko pojavijo pri več kot 1 bolniku od 10) so driska, navzeja (slabost), bruhanje, trombocitopenija (nizko število trombocitov) in zlomi kosti.
The active substance in Xofigo, radium-223, emits short-range radiation known as alpha particles. 
Učinkovina v zdravilu Xofigo, [223Ra]radij, oddaja sevanje kratkega dosega, imenovano delci alfa.
How does Xofigo work? 
Kako zdravilo Xofigo deluje?
How is Xofigo used? 
Kako se zdravilo Xofigo uporablja?
For the full list of side effects of Xofigo, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Xofigo, glejte navodilo za uporabo.
Regarding its safety, several measures have been put in place to minimise the risks of the medicine such as bone fractures1 The radiation emitted by Xofigo has a shorter range than the radiation of currently available radiopharmaceuticals. 
Kar zadeva njegovo varnost, je bilo sprejetih več ukrepov za zmanjšanje tveganj pri tem zdravilu, na primer zlomov kosti1.
Xofigo contains the active substance radium-223 dichloride. 
Zdravilo Xofigo vsebuje učinkovino [223Ra]radijev klorid.
The signs and symptoms of progressive disease such as bone pain also took longer to develop in patients given Xofigo. 
Pri bolnikih, ki so prejemali zdravilo Xofigo, je trajalo dalj tudi do pojava znakov in simptomov napredujoče bolezni, na primer bolečine v kosteh.
Take your dose once a day. 
Odmerek vzemite enkrat na dan.
These changes were each in the direction of improved lipid responses and were sustained over 2 years. 
Vse te spremembe so bile v smeri izboljšanih odzivov lipidov in so se ohranile v obdobju 2 let.
Children younger than 6 years 
Otroci, mlajši od 6 let
Your doctor may increase your dose to find the right amount of CRESTOR for you. 
Vaš zdravnik lahko poveča vaš odmerek, da bi našel ustrezen odmerek zdravila CRESTOR za vas.
This trial (n=176) was not suited for comparison of rare adverse drug events. 
To preskušanje (n = 176) ni bilo primerno za primerjavo redkih neželenih učinkov zdravila.
This means you are at risk from a heart attack or stroke. 
To pomeni, da vas ogroža srčni infarkt ali možganska kap.
What you need to know before you take CRESTOR 
Kaj morate vedeti, preden boste vzeli zdravilo CRESTOR